Gene:
ERBB3
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  HER3
PharmGKB Accession Id: PA27846

Details

Cytogenetic Location: chr12 : q13.2 - q13.2
GP mRNA Boundary: chr12 : 56473809 - 56497291
GP Gene Boundary: chr12 : 56463809 - 56500291
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.

External Pathways

Links to non-PharmGKB pathways.

  1. a6b1 and a6b4 Integrin signaling - (Pathway Interaction Database NCI-Nature Curated)
  2. neuroregulin receptor degredation protein-1 controls erbb3 receptor recycling - (BioCarta via Pathway Interaction Database)
  3. role of erbb2 in signal transduction and oncology - (BioCarta via Pathway Interaction Database)

Publications related to ERBB3: 10

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature genetics. 2013. Toy Weiyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer research. 2010. Huang Xiaoping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PloS one. 2010. Nencioni Alessio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC cancer. 2009. Glaysher Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway. American journal of human genetics. 2007. Narkis Ginat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Trastuzumab--mechanism of action and use in clinical practice. The New England journal of medicine. 2007. Hudis Clifford A. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, N.Y.). 2007. Engelman Jeffrey A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A five-gene signature and clinical outcome in non-small-cell lung cancer. The New England journal of medicine. 2007. Chen Hsuan-Yu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene. 1997. Bates N P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. European journal of cancer (Oxford, England : 1990). 1996. Wärri A M, et al. PubMed

LinkOuts

Entrez Gene:
2065
OMIM:
190151
607598
UCSC Genome Browser:
NM_001982
RefSeq RNA:
NM_001005915
NM_001982
RefSeq Protein:
NP_001005915
NP_001973
RefSeq DNA:
AC_000055
AC_000144
NC_000012
NG_011529
NT_029419
NW_001838059
NW_925395
UniProtKB:
B3KWG5_HUMAN (B3KWG5)
ERBB3_HUMAN (P21860)
Ensembl:
ENSG00000065361
GenAtlas:
ERBB3
GeneCard:
ERBB3
MutDB:
ERBB3
ALFRED:
LO040913R
HuGE:
ERBB3
Comparative Toxicogenomics Database:
2065
ModBase:
P21860
HumanCyc Gene:
HS00838
HGNC:
3431

Common Searches